The EmERGE platform delivered secure smartphone access to current and historical laboratory results plus direct clinician feedback for people living with HIV. The study was an observational, longitudinal evaluation conducted at a national HIV referral centre in Zagreb, Croatia. Investigators enrolled EmERGE users and non-users to capture both patient-reported activation and routine clinical outcomes; the primary analytical cohort included EmERGE users with repeated PAM-13 assessments (n = 304). Additional app users (n = 238) and non-users (n = 162) provided descriptive clinical safety data. The authors reported a median follow-up of 3.2 years for PAM-13 measurement and used mixed-effects models to analyse longitudinal trajectories.
The 13-item PAM-13 instrument quantified participants' knowledge, skills and confidence for health self-management. Mean activation at baseline was 69.6 and at three years was 68.9, indicating overall stability in the cohort's activation levels across the median 3.2-year follow-up. The study team observed that most participants maintained high activation throughout follow-up; scores did not trend toward a clinically meaningful decline at the group level. Mixed-effects modelling accommodated repeated measures and allowed investigators to characterise individual trajectories over time. The source did not report more granular item-level PAM-13 data or thresholds for clinically important change beyond the reported means.
Age emerged as a modifier of longitudinal activation patterns in this cohort. The investigators reported a statistically significant interaction between age and time (interaction p = 0.004), with older participants showing an increasing probability of lower activation over the study period. Younger and middle-aged participants were more likely to maintain high activation, while the probability of declining activation rose with advancing age according to the models. The authors noted this divergence and recommended targeted, age-specific strategies to prevent long-term engagement declines among older people living with HIV. The paper did not specify particular intervention designs or implementation details for these age-focused approaches.
Clinical safety outcomes were captured descriptively across app users and non-users. Investigators reported sustained high rates of viral suppression in all groups during routine practice. Major clinical events were described as infrequent, and the study team interpreted these data as showing no evidence of increased clinical risk associated with the EmERGE pathway. The source abstract does not enumerate specific event types, counts, or time-to-event analyses; nor does it provide numerical viral suppression rates in the abstract text. Those details may be in the full text, but they were not reported in the source abstract.
This study documents that integration of EmERGE into routine care can be achieved without immediate compromise of clinical safety and with sustained patient activation for most users. The cohort design — longitudinal and observational — enabled real-world assessment over a median 3.2 years, but it also imposes limits on causal inference. The work was conducted at a single national referral centre in Zagreb, Croatia; this setting may affect generalisability to other health systems or populations. The abstract does not report item-level PAM-13 changes, subgroup sample sizes beyond the stated cohorts, or detailed event counts for major clinical outcomes. Investigators flagged the need for targeted strategies for older participants but did not present specific intervention models or timing. These gaps identify concrete unanswered questions: which age-tailored interventions prevent activation decline, and how do detailed clinical-event rates compare when reported fully? The source did not report regulatory milestones or broader implementation outcomes such as cost, interoperability metrics, or patient usability data.
Limitations documented or implied in the source include the observational design and single-centre setting; additional limitations — such as potential selection bias among app users or missing data patterns — are not described in the abstract. Future reports or the full manuscript may address these items and provide the more granular clinical and PAM-13 data that would inform implementation decisions for other clinics.